1.
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
2.
|
Bosch FX and de Sanjose S: Chapter 1:
Human papillomavirus and cervical cancer - burden and assessment of
causality. J Natl Cancer Inst Monogr. 3–13. 2003. View Article : Google Scholar : PubMed/NCBI
|
3.
|
Munoz N: Human papillomavirus and cancer:
the epidemiological evidence. J Clin Virol. 19:1–5. 2000.
View Article : Google Scholar : PubMed/NCBI
|
4.
|
Andrae B, Kemetli L, Sparen P, Silfverdal
L, Strander B, Ryd W, et al: Screening-preventable cervical cancer
risks: evidence from a nationwide audit in Sweden. J Natl Cancer
Inst. 100:622–629. 2008. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Sankaranarayanan R: HPV vaccination: the
promise and problems. Indian J Med Res. 130:322–326.
2009.PubMed/NCBI
|
6.
|
Centers for Disease Control and
Prevention: Progress toward implementation of human papillomavirus
vaccination - the Americas, 2006–2010. MMWR Morb Mortal Wkly Rep.
60:1382–1384. 2011.PubMed/NCBI
|
7.
|
Lu B, Kumar A, Castellsague X and Giuliano
AR: Efficacy and safety of prophylactic vaccines against cervical
HPV infection and diseases among women: a systematic review and
meta-analysis. BMC Infect Dis. 11:132011. View Article : Google Scholar : PubMed/NCBI
|
8.
|
Smith JS, Lindsay L, Hoots B, Keys J,
Franceschi S, Winer R, et al: Human papillomavirus type
distribution in invasive cervical cancer and high-grade cervical
lesions: a meta-analysis update. Int J Cancer. 121:621–632. 2007.
View Article : Google Scholar : PubMed/NCBI
|
9.
|
Committee on Infectious Diseases: HPV
vaccine recommendations. Pediatrics. 129:602–605. 2012. View Article : Google Scholar
|
10.
|
Agurto I, Bishop A, Sanchez G, Betancourt
Z and Robles S: Perceived barriers and benefits to cervical cancer
screening in Latin America. Prev Med. 39:91–98. 2004. View Article : Google Scholar : PubMed/NCBI
|
11.
|
Matos E, Loria D, Amestoy GM, Herrera L,
Prince MA, Moreno J, et al: Prevalence of human papillomavirus
infection among women in Concordia, Argentina: a population-based
study. Sex Transm Dis. 30:593–599. 2003. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Bruni L, Diaz M, Castellsague X, Ferrer E,
Bosch FX and de Sanjose S: Cervical human papillomavirus prevalence
in 5 continents: meta-analysis of 1 million women with normal
cytological findings. J Infect Dis. 202:1789–1799. 2010. View Article : Google Scholar : PubMed/NCBI
|
13.
|
5th Global Meeting on Implementing, New
and Under-utilized Vaccines, 22–24 June 2011 [Internet]. Geneva,
Switzerland: New and Under-utilized Vaccines Implementation (NUVI)
- World Health Organization (WHO); 2011, [updated 2011; cited 2011
20 Oct]. Available from: http://www.who.int/nuvi/2011_meeting_summary_delivery-strategies/en/.
|
14.
|
Vacuna contra el Virus del Papiloma Humano
(VPH) [Internet]. Buenos Aires, Republica Argentina: Ministerio de
Salud; 2013, [cited 2013 06 Mars]. Available from: http://www.msal.gov.ar/index.php/programas-y-planes/185-vph.
|
15.
|
Colantonio L, Gomez JA, Demarteau N,
Standaert B, Pichon-Riviere A and Augustovski F: Cost-effectiveness
analysis of a cervical cancer vaccine in five Latin American
countries. Vaccine. 27:5519–5529. 2009. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Arrossi S, Maceira V, Paolino M and
Sankaranarayanan R: Acceptability and uptake of HPV vaccine in
Argentina before its inclusion in the immunization program: a
population-based survey. Vaccine. 30:2467–2474. 2012. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Sundstrom K, Tran TN, Lundholm C, Young C,
Sparen P and Dahlstrom LA: Acceptability of HPV vaccination among
young adults aged 18–30 years - a population based survey in
Sweden. Vaccine. 28:7492–7500. 2010.
|
18.
|
Black LL, Zimet GD, Short MB, Sturm L and
Rosenthal SL: Literature review of human papillomavirus vaccine
acceptability among women over 26 years. Vaccine. 27:1668–1673.
2009.PubMed/NCBI
|
19.
|
CDC Vaccine price list [Internet].
Atlanta, USA: Centers for Disease Control and Prevention; 2011,
[updated 15 Dec 2011; cited 2011 29 Dec]. Available from:
http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm.
|
20.
|
Brewer NT and Fazekas KI: Predictors of
HPV vaccine acceptability: a theory-informed, systematic review.
Prev Med. 45:107–114. 2007. View Article : Google Scholar : PubMed/NCBI
|
21.
|
Dahlstrom LA, Tran TN, Lundholm C, Young
C, Sundstrom K and Sparen P: Attitudes to HPV vaccination among
parents of children aged 12–15 years-a population-based survey in
Sweden. Int J Cancer. 126:500–507. 2010.
|
22.
|
Woodhall SC, Lehtinen M, Verho T, Huhtala
H, Hokkanen M and Kosunen E: Anticipated acceptance of HPV
vaccination at the baseline of implementation: a survey of parental
and adolescent knowledge and attitudes in Finland. J Adolesc
Health. 40:466–469. 2007. View Article : Google Scholar : PubMed/NCBI
|
23.
|
Donders GG, Gabrovska M, Bellen G, Van
Keirsbilck J, Van Den Bosch T, Riphagen I, et al: Knowledge of
cervix cancer, human papilloma virus (HPV) and HPV vaccination at
the moment of introduction of the vaccine in women in Belgium. Arch
Gynecol Obstet. 277:291–198. 2008. View Article : Google Scholar : PubMed/NCBI
|
24.
|
Gamarra CJ, Paz EP and Griep RH:
Knowledge, attitudes and practice related to Papanicolaou smear
test among Argentina’s women. Rev Saude Publica. 39:270–276.
2005.(In Portuguese).
|